Skip header and navigation

Refine By

46 records – page 1 of 5.

Adiponectin: a link between excess adiposity and associated comorbidities?

https://arctichealth.org/en/permalink/ahliterature47470
Source
J Mol Med. 2002 Nov;80(11):696-702
Publication Type
Article
Date
Nov-2002
Author
Olavi Ukkola
Merja Santaniemi
Author Affiliation
Department of Internal Medicine and Biocenter Oulu, University of Oulu, Kajaanintie 50/P.O. Box 5000, 90220 Oulu, Finland. olavi.ukkola@oulu.fi
Source
J Mol Med. 2002 Nov;80(11):696-702
Date
Nov-2002
Language
English
Publication Type
Article
Keywords
Adipocytes - physiology
Adiponectin
Adipose Tissue - physiology
Comorbidity
Diabetes Mellitus, Type 2 - physiopathology
Humans
Intercellular Signaling Peptides and Proteins
Obesity - physiopathology
Proteins - physiology
Abstract
Adiponectin is a novel polypeptide that is highly specific to adipose tissue. In contrast to other adipocytokines, adiponectin levels are decreased in obesity and associated comorbidities, such as type 2 diabetes. Decreased expression of adiponectin is correlated with insulin resistance. It has been suggested that several agents, such as tumor necrosis factor alpha, could mediate their effects on insulin metabolism through modulating adiponectin secretion from adipocytes. The mechanisms for the development of atherosclerotic vascular disease in obese individuals are largely unknown. Several findings support the interesting hypothesis that adiponectin could be a link between obesity and related atherosclerosis. First, adiponectin levels are lower in patients with coronary artery disease. Second, adiponectin modulates endothelial function and has an inhibitory effect on vascular smooth muscle cell proliferation. Moreover, adiponectin is accumulated more preferably to the injured vascular wall than intact vessels and has been shown to suppress macrophage-to-foam cell transformation. Adiponectin may also be involved in the modulation of inflammation. Thiazolidinediones, antiatherogenic and other effects have been explained by their direct enhancing effect on adiponectin. In conclusion, adiponectin has anti-inflammatory and antiatherogeneic effects as well as multiple beneficial effects on metabolism. Therefore it is not a surprise that adiponectin therapy has been tested in animal models of obesity, and it has been shown to ameliorate hyperglycemia and hyperinsulinemia without inducing weight gain or even inducing weight loss in some studies. Unlike agents that exert their effects centrally, adiponectin's effects seem to be peripherally mediated. The evidence of an association between adiponectin and the metabolic and cardiovascular complications of obesity is growing all the time.
PubMed ID
12436346 View in PubMed
Less detail

Adiponectin polymorphisms, adiposity and insulin metabolism: HERITAGE family study and Oulu diabetic study.

https://arctichealth.org/en/permalink/ahliterature47016
Source
Ann Med. 2005;37(2):141-50
Publication Type
Article
Date
2005
Author
Olavi Ukkola
Merja Santaniemi
Tuomo Rankinen
Arthur S Leon
James S Skinner
Jack H Wilmore
D C Rao
Richard Bergman
Y Antero Kesäniemi
Claude Bouchard
Author Affiliation
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge 70808-4124, USA.
Source
Ann Med. 2005;37(2):141-50
Date
2005
Language
English
Publication Type
Article
Keywords
Adipocytes - metabolism
Adiponectin
Adipose Tissue - metabolism
African Continental Ancestry Group - genetics
Case-Control Studies
Diabetes Mellitus, Type 2 - genetics
European Continental Ancestry Group - genetics
Female
Finland
Gene Frequency
Haplotypes
Histidine
Humans
Insulin - metabolism
Intercellular Signaling Peptides and Proteins - genetics
Male
Middle Aged
Polymorphism, Genetic
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Risk factors
Tyrosine
Abstract
AIMS/HYPOTHESIS: Adiponectin is an adipocytokine with lowered blood levels in obesity and Type 2 diabetes mellitus. We sought to define the specific effects of different alleles of the gene encoding adiponectin. METHODS: We studied the associations of adiponectin gene sequence variations with body fat distribution and insulin indices in 503 White and 276 Black subjects of the HERITAGE Family Study cohort and subjects from a Finnish population. RESULTS: The His111 allele frequency of the Tyr111 His polymorphism in Finnish Type 2 diabetic subjects (n=254) was higher (5.1%) than in control subjects (n=270) (2.6%; P = 0.033). In the HERITAGE cohort, the His111 allele was associated with a lower insulin sensitivity index (P = 0.018) and a higher acute insulin response to glucose (P = 0.0098) in Whites. Other variants showed associations with adiposity and plasma lipid values only in Blacks. Among Blacks, the IVS2+G62T variant was associated with body fat (P = 0.002) and total cholesterol values (P = 0.005), and the Gly15Gly variant with cholesterol (P = 0.009) and triglyceride (P = 0.05) levels. The haplotype derived from these two polymorphisms was associated with total body fat, while the IVS2+G62T and Tyr111His-haplotype was associated with body fat and disposition index. CONCLUSIONS: The carriers of the His111 allele may have a higher risk of developing Type 2 diabetes mellitus. Racial differences were found between Blacks and Whites in body composition and lipids according to ACDC genotypes. Sequence variants in the adiponectin gene appear to be associated with diabetes and diabetes-related phenotypes.
PubMed ID
16028335 View in PubMed
Less detail

Ambulatory Blood Pressure Characteristics and Long-Term Risk for Atrial Fibrillation.

https://arctichealth.org/en/permalink/ahliterature289822
Source
Am J Hypertens. 2017 Mar 01; 30(3):264-270
Publication Type
Journal Article
Date
Mar-01-2017
Author
Juha S Perkiömäki
Santeri Nortamo
Antti Ylitalo
Antero Kesäniemi
Olavi Ukkola
Heikki V Huikuri
Author Affiliation
Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
Source
Am J Hypertens. 2017 Mar 01; 30(3):264-270
Date
Mar-01-2017
Language
English
Publication Type
Journal Article
Keywords
Adult
Atrial Fibrillation - epidemiology
Blood pressure
Blood Pressure Monitoring, Ambulatory
Emergencies - epidemiology
Female
Finland - epidemiology
Follow-Up Studies
Humans
Hypertension - epidemiology - physiopathology
Male
Middle Aged
Predictive value of tests
Risk assessment
Risk factors
Abstract
We hypothesized that elevated nighttime systolic ambulatory blood pressure (ABP) yields additional information compared with daytime systolic ABP for the long-term risk of atrial fibrillation (AF) and perhaps should be taken into account in treatment strategies for preventing the increasing burden of AF during aging.
A total of 903 subjects with or without hypertension aged 40 to 59 years, who were recruited to the Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study, underwent ABP monitoring, thorough clinical examinations and laboratory tests.
After an average of 16.4 ± 3.6 years of follow-up, 91 (10%) of the study subjects had experienced a new-onset AF requiring a hospital emergency room or hospital visit. Of the components of baseline ABP, the nighttime mean systolic blood pressure had the strongest univariable association with the occurrence of AF (120.8 ± 15.9 vs. 116.4 ± 14.1 mm Hg, P = 0.006, in subjects with vs. without the occurrence AF). When the univariable predictors of AF, such as age, sex, body mass index, height, smoking history, alanine aminotransferase, uric acid, and fasting plasma glucose, were entered in the multivariable Cox hazards model, age (P
PubMed ID
27852579 View in PubMed
Less detail

Ambulatory Blood Pressure Characteristics and Long-Term Risk for Atrial Fibrillation.

https://arctichealth.org/en/permalink/ahliterature277774
Source
Am J Hypertens. 2016 Nov 15;
Publication Type
Article
Date
Nov-15-2016
Author
Juha S Perkiömäki
Santeri Nortamo
Antti Ylitalo
Antero Kesäniemi
Olavi Ukkola
Heikki V Huikuri
Source
Am J Hypertens. 2016 Nov 15;
Date
Nov-15-2016
Language
English
Publication Type
Article
Abstract
We hypothesized that elevated nighttime systolic ambulatory blood pressure (ABP) yields additional information compared with daytime systolic ABP for the long-term risk of atrial fibrillation (AF) and perhaps should be taken into account in treatment strategies for preventing the increasing burden of AF during aging.
A total of 903 subjects with or without hypertension aged 40 to 59 years, who were recruited to the Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study, underwent ABP monitoring, thorough clinical examinations and laboratory tests.
After an average of 16.4 ± 3.6 years of follow-up, 91 (10%) of the study subjects had experienced a new-onset AF requiring a hospital emergency room or hospital visit. Of the components of baseline ABP, the nighttime mean systolic blood pressure had the strongest univariable association with the occurrence of AF (120.8 ± 15.9 vs. 116.4 ± 14.1 mm Hg, P = 0.006, in subjects with vs. without the occurrence AF). When the univariable predictors of AF, such as age, sex, body mass index, height, smoking history, alanine aminotransferase, uric acid, and fasting plasma glucose, were entered in the multivariable Cox hazards model, age (P
PubMed ID
27852579 View in PubMed
Less detail

Answer to Dr. Sabours letter about our article 'the validity of hospital discharge register data on non-ST-elevation and ST-elevation myocardial infarction in Finland'.

https://arctichealth.org/en/permalink/ahliterature305416
Source
Scand Cardiovasc J. 2020 10; 54(5):338
Publication Type
Letter
Comment
Date
10-2020
Author
Marjo Okkonen
Aki S Havulinna
Olavi Ukkola
Veikko Salomaa
Author Affiliation
Research Unit of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Source
Scand Cardiovasc J. 2020 10; 54(5):338
Date
10-2020
Language
English
Publication Type
Letter
Comment
Keywords
Finland - epidemiology
Hospitals
Humans
Non-ST Elevated Myocardial Infarction
Patient Discharge
ST Elevation Myocardial Infarction - diagnosis - epidemiology - therapy
Notes
CommentOn: Scand Cardiovasc J. 2020 Apr;54(2):108-114 PMID 31701776
CommentOn: Scand Cardiovasc J. 2020 Oct;54(5):336-337 PMID 32998593
PubMed ID
32597231 View in PubMed
Less detail

Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking hypertensive men.

https://arctichealth.org/en/permalink/ahliterature67351
Source
J Hypertens. 2002 Dec;20(12):2371-8
Publication Type
Article
Date
Dec-2002
Author
Jarkko Karvonen
Heikki Kauma
Kari Kervinen
Olavi Ukkola
Maire Rantala
Markku Päivänsalo
Markku J Savolainen
Y Antero Kesäniemi
Author Affiliation
Department of Internal Medicine, University of Oulu, PO Box 5000, FIN-90014, Finland. jakarvon@paju.oulu.fi
Source
J Hypertens. 2002 Dec;20(12):2371-8
Date
Dec-2002
Language
English
Publication Type
Article
Keywords
Adult
Apolipoproteins E - genetics
Carotid Artery Diseases - etiology
Case-Control Studies
Cross-Sectional Studies
Genetic Predisposition to Disease
Heterozygote
Humans
Hypertension - genetics - ultrasonography
Intracranial Arteriosclerosis - etiology
Male
Middle Aged
Polymorphism, Genetic
Research Support, Non-U.S. Gov't
Smoking - adverse effects
Tunica Intima - ultrasonography
Tunica Media - ultrasonography
Abstract
OBJECTIVE: Smoking is a risk factor for increased carotid artery intima-media thickness (IMT). The apolipoprotein E (apoE) 4 allele has been associated with cardiovascular diseases, but the role of apoE in regard to intima-media thickness (IMT) has remained controversial. The objective was to investigate whether there is some gene-environment interaction between smoking and apoE polymorphism.DESIGN Cross-sectional case-control study. METHODS: IMTs of 511 hypertensive and control men were measured ultrasonographically and the apoE genotypes were determined. Genotypes with the 4 allele were pooled into one group and the genotypes without it into another. RESULTS: A significant interaction between the 4 allele and smoking affecting IMT was observed among the hypertensive smokers, as assessed by analysis of covariance. The mean carotid IMT was significantly greater (1.01 versus 0.90 mm, P = 0.003) in the 4 carriers than in the subjects without 4 among the hypertensive smokers. The number of plaques was also significantly higher. No differences were found in the other subjects (hypertensive non-smokers or controls). Linear regression analysis indicated that the 4 allele was an independent determinant of IMT in the hypertensive smokers but not in the other subjects. The estimated average effect of the 4 allele on the mean IMT in the hypertensive smokers was 0.088 mm (P
Notes
Comment In: J Hypertens. 2002 Dec;20(12):2327-912473848
PubMed ID
12473860 View in PubMed
Less detail

A blood pressure genetic risk score is a significant predictor of incident cardiovascular events in 32,669 individuals.

https://arctichealth.org/en/permalink/ahliterature115422
Source
Hypertension. 2013 May;61(5):987-94
Publication Type
Article
Date
May-2013
Author
Aki S Havulinna
Johannes Kettunen
Olavi Ukkola
Clive Osmond
Johan G Eriksson
Y Antero Kesäniemi
Antti Jula
Leena Peltonen
Kimmo Kontula
Veikko Salomaa
Christopher Newton-Cheh
Author Affiliation
Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Source
Hypertension. 2013 May;61(5):987-94
Date
May-2013
Language
English
Publication Type
Article
Keywords
Adult
Blood Pressure - genetics
Cardiovascular Diseases - epidemiology - ethnology - genetics
Cohort Studies
Cross-Sectional Studies
Female
Finland - epidemiology
Follow-Up Studies
Genome-Wide Association Study
Genotype
Humans
Hypertension - genetics
Incidence
Longitudinal Studies
Male
Middle Aged
Polymorphism, Single Nucleotide - genetics
Prospective Studies
Retrospective Studies
Risk factors
Abstract
Recent genome-wide association studies have identified genetic variants associated with blood pressure (BP). We investigated whether genetic risk scores (GRSs) constructed of these variants would predict incident cardiovascular disease (CVD) events. We genotyped 32 common single nucleotide polymorphisms in several Finnish cohorts, with up to 32,669 individuals after exclusion of prevalent CVD cases. The median follow-up was 9.8 years, during which 2295 incident CVD events occurred. We created GRSs separately for systolic BP and diastolic BP by multiplying the risk allele count of each single nucleotide polymorphism by the effect size estimated in published genome-wide association studies. We performed Cox regression analyses with and without adjustment for clinical factors, including BP at baseline in each cohort. The results were combined by inverse variance-weighted fixed-effects meta-analysis. The GRSs were strongly associated with systolic BP and diastolic BP, and baseline hypertension (all P
Notes
Cites: Nat Genet. 2009 Jun;41(6):677-8719430479
Cites: Nat Genet. 2009 Jun;41(6):666-7619430483
Cites: PLoS Genet. 2010 Oct;6(10):e100117721082022
Cites: Stat Med. 2011 Jan 15;30(1):11-2121204120
Cites: Hypertension. 2011 May;57(5):903-1021444836
Cites: Nature. 2011 Oct 6;478(7367):103-921909115
Cites: Hypertension. 2011 Dec;58(6):1079-8522025373
Cites: Int J Epidemiol. 2010 Apr;39(2):504-1819959603
Cites: Hypertension. 2000 Oct;36(4):477-8311040222
Cites: Stat Med. 2002 Jun 15;21(11):1539-5812111919
Cites: Nat Genet. 2003 Feb;33(2):177-8212524541
Cites: JAMA. 2003 May 21;289(19):2560-7212748199
Cites: Lancet. 1990 Mar 31;335(8692):765-741969518
Cites: Lancet. 1990 Apr 7;335(8693):827-381969567
Cites: Hypertension. 1996 Dec;28(6):1070-58952598
Cites: Stat Med. 1997 May 15;16(9):965-809160492
Cites: Eur J Cardiovasc Prev Rehabil. 2005 Apr;12(2):132-715785298
Cites: Stat Med. 2005 Oct 15;24(19):2911-3516152135
Cites: N Engl J Med. 2005 Oct 27;353(17):1802-916251536
Cites: Eur J Cardiovasc Prev Rehabil. 2007 Jun;14(3):380-517568236
Cites: Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-1217569110
Cites: Lancet. 2010 Mar 13;375(9718):895-90520226988
Comment In: Hypertension. 2013 May;61(5):961-323509079
PubMed ID
23509078 View in PubMed
Less detail

Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study).

https://arctichealth.org/en/permalink/ahliterature295225
Source
PLoS One. 2018; 13(10):e0205454
Publication Type
Journal Article
Date
2018
Author
Helena Kattelus
Y Antero Kesäniemi
Heikki Huikuri
Olavi Ukkola
Author Affiliation
Research Unit of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Source
PLoS One. 2018; 13(10):e0205454
Date
2018
Language
English
Publication Type
Journal Article
Abstract
Relation between atrial fibrillation (AF) and cancer is known but not very well understood. The purpose of this prospective study was to find out whether subjects with cancer were at greater risk of AF than subjects without cancer.
The study was based on the OPERA (Oulu Project Elucidating Risk of Atherosclerosis) material and had 1045 subjects and the mean follow-up time of 16.3 years. During the follow-up AF and cancer diagnosis were made (atrial flutter included) if these events were listed in the National Death Registry and/or hospital discharge registry.
In this study 130 subjects (12%) had cancer and 19% of these had AF, whereas only 9% of those without cancer experienced AF during the follow-up (p
Notes
Cites: Surg Today. 2016 Aug;46(8):877-86 PMID 26471506
Cites: Ann Thorac Surg. 2010 Aug;90(2):368-74 PMID 20667313
Cites: Anticancer Res. 2012 Sep;32(9):4077-84 PMID 22993364
Cites: PLoS One. 2015 Nov 16;10(11):e0142937 PMID 26571029
Cites: Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S120-3 PMID 15683477
Cites: Eur Heart J. 2013 Apr;34(15):1102-11 PMID 22789916
Cites: Int J Cardiol. 2017 Aug 1;240:196-202 PMID 28390744
Cites: J Cardiovasc Electrophysiol. 2014 Jul;25(7):719-24 PMID 24602026
Cites: J Med Imaging Radiat Oncol. 2017 Feb;61(1):85-92 PMID 27554594
Cites: Interact Cardiovasc Thorac Surg. 2017 Feb 1;24(2):260-264 PMID 27803121
Cites: Lancet. 2012 Feb 18;379(9816):648-61 PMID 22166900
Cites: PLoS One. 2014 Aug 13;9(8):e102861 PMID 25119880
Cites: Surg Today. 2017 Feb;47(2):252-258 PMID 27382978
Cites: Intern Emerg Med. 2012 Oct;7(5):431-8 PMID 21968511
Cites: Arq Bras Cardiol. 2015 Nov;105(5):519-26 PMID 26577719
Cites: Circulation. 2003 Dec 16;108(24):3006-10 PMID 14623805
Cites: J Am Coll Cardiol. 2014 Mar 18;63(10):945-53 PMID 24361314
Cites: Int J Cardiol. 2013 May 10;165(2):355-7 PMID 22989607
Cites: Intern Emerg Med. 2008 Sep;3(3):227-31 PMID 18320149
Cites: Circulation. 2013 Nov 12;128(20):2192-201 PMID 24016454
Cites: Am J Cardiol. 2015 Apr 15;115(8):1090-4 PMID 25711434
Cites: Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70 PMID 25712077
Cites: Eur Heart J. 2016 Oct 7;37(38):2893-2962 PMID 27567408
Cites: J Intern Med. 1999 Feb;245(2):163-74 PMID 10081519
Cites: Clin Epidemiol. 2013 Nov 01;5(Suppl 1):3-29 PMID 24227920
PubMed ID
30289944 View in PubMed
Less detail

Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study).

https://arctichealth.org/en/permalink/ahliterature298988
Source
PLoS One. 2018; 13(10):e0205454
Publication Type
Journal Article
Date
2018
Author
Helena Kattelus
Y Antero Kesäniemi
Heikki Huikuri
Olavi Ukkola
Author Affiliation
Research Unit of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Source
PLoS One. 2018; 13(10):e0205454
Date
2018
Language
English
Publication Type
Journal Article
Keywords
Atrial Fibrillation - epidemiology - etiology
Case-Control Studies
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasms - complications - epidemiology
Prospective Studies
Registries
Risk factors
Abstract
Relation between atrial fibrillation (AF) and cancer is known but not very well understood. The purpose of this prospective study was to find out whether subjects with cancer were at greater risk of AF than subjects without cancer.
The study was based on the OPERA (Oulu Project Elucidating Risk of Atherosclerosis) material and had 1045 subjects and the mean follow-up time of 16.3 years. During the follow-up AF and cancer diagnosis were made (atrial flutter included) if these events were listed in the National Death Registry and/or hospital discharge registry.
In this study 130 subjects (12%) had cancer and 19% of these had AF, whereas only 9% of those without cancer experienced AF during the follow-up (p
PubMed ID
30289944 View in PubMed
Less detail

46 records – page 1 of 5.